UBS downgrades Carlyle Group stock rating on growth concerns

UBS downgraded Carlyle Group (CG) from Buy to Neutral, lowering its price target to $47. Analysts cited concerns about growth and reduced fee-related earnings forecasts. The stock is down 26.9% year-to-date, trading at $42.31. UBS also lowered its 2027 and 2028 earnings estimates. Carlyle's Q3 2026 results beat expectations but the stock declined due to growth outlook uncertainties.

Original reporting
Published Nov 10, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CG
Bearish
high confidence
Mentioned
$CG
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGBearishHigh
01

Why it matters

The downgrade reflects concerns about Carlyle's ability to meet its 2028 growth targets, which could lead to a short‑term sell‑off.

02

Market read

Analyst downgrade with a target cut is a fresh, material catalyst for CG, likely prompting immediate trading action.

03

What to watch

Potential upside from Carlyle's strong fundraising momentum and record fee‑related earnings could mitigate the downgrade impact.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

UBS analysts lowered their expectations for Carlyle's 2027‑2028 earnings and fee‑related growth, aligning with a broader sector focus on growth sustainability.

Company-level read

Ticker impact

$CGBearishHigh confidence
Context

UBS downgraded Carlyle Group to Neutral and cut the price target to $47, citing weaker growth expectations and lower earnings forecasts.

Expected impact

likely pressure as the market prices in weaker growth and earnings outlook

Evidence & confidence

Analyst downgrade with a target cut is a fresh catalyst that typically triggers sell‑offs, especially given the stock already trades below the new target.

Market effects

May weigh on other private‑equity and alternative‑asset managers as peers face similar growth scrutiny.

Limited to U.S. markets; no broader regional effect.

Low global relevance beyond the private‑equity sector.

Counterpoint

Some investors may see the price already discounted and view the downgrade as a buying opportunity if they believe growth can rebound.

Key entities

  • The Carlyle Group LP

    Global private‑equity firm whose stock is being downgraded.

  • UBS

    Investment bank providing the downgrade and revised price target.

Related articles

$CGHigh

Why is Carlyle stock sliding today?

Carlyle Group (CG) stock fell 0.8% to $41.99 in pre-market trading after UBS downgraded it to Neutral, cutting its price target to $47 from $60. UBS cited reduced confidence in Carlyle's growth trajectory and ability to meet 2028 financial targets. Other analysts have also lowered price targets. The stock is below its 52-week high of $67.30 but above its low of $35.41.

$CGMed

Carlyle Group Targets First Buyout Fund Close as $200 Billion Fundraising Push Takes Shape

Carlyle Group (CG) aims to close its first buyout fund as part of a $200 billion fundraising initiative. The company announced its first defense fund deal, Secturion, and highlighted a $5 billion structured transaction via AlpInvest. Carlyle expects growth in credit secondaries and fee-related earnings, with a focus on private equity products. The firm is also restructuring its European buyout team, with the next fund expected to be smaller than its predecessor.

$CGMed

Carlyle and EBRD Agree Sale

Carlyle (CG) and EBRD agreed to sell Black Sea Oil & Gas (BSOG), Romania's largest offshore gas producer, to Mazarine Energy. The deal, pending approval, transfers ownership of BSOG, which supplies 12% of Romania's gas demand, to Mazarine. Carlyle invested over $400M in BSOG's Midia Gas Development project. BSOG will remain the operator, ensuring continuity.

$CGHighAI 8/10

Carlyle 3Q 2026: Revenue $334.1M, EPS ($0.02) — 10-Q Summary

Carlyle reported Q3 2026 revenue of $334.1M, a slight YoY decrease, and a net loss of $0.02 per share. Fund management fees and performance allocations declined, while principal investment income and compensation expenses fell. Distributable earnings rose to $432.5M, with $11.0B deployed and $10.8B in inflows. AUM totaled $478.5B.